Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine

Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) signaling are being explored as prophylactic treatments for migraine. Erenumab (AMG 334) is the first potent, selective, and competitive human mAb antagonist of the CGRP receptor. We report the data from two phase I studie...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical pharmacology and therapeutics Vol. 103; no. 5; p. 815
Main Authors:	de Hoon, Jan, Van Hecken, Anne, Vandermeulen, Corinne, Yan, Lucy, Smith, Brian, Chen, Jiyun Sunny, Bautista, Edgar, Hamilton, Lisa, Waksman, Javier, Vu, Thuy, Vargas, Gabriel
Format:	Journal Article
Language:	English
Published:	United States 01.05.2018
Subjects:	Adolescent Adult Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Calcitonin Gene-Related Peptide - metabolism Calcitonin Gene-Related Peptide Receptor Antagonists - therapeutic use Double-Blind Method Female Healthy Volunteers Humans Male Middle Aged Migraine Disorders - drug therapy Migraine Disorders - metabolism Signal Transduction - drug effects Young Adult
ISSN:	1532-6535, 1532-6535
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!